Gilead reports its investigational single tablet of bictegravir and lenacapavir was efficacious in people with HIV who are virologically suppressed and who switched from taking multitablet regimens. The company says its phase 3 study results will form the basis for its future regulatory submissions.
During National C difficile Awareness Month, the Peggy Lillis Foundation is working toward greater awareness about prescribing practices as well as cleaning methods that can prevent infections.
The tool's developer, LIV Process, says it has created a water-based reagent that illuminates Clostridioides difficile on surfaces so teams can verify cleaning in real time.
Rachel Britt, PharmD, BCIDP, provides insights on an evolving understanding of the long-time antibiotic’s limitations for these infections and provides guidance on other agents and the role of diagnostics in finding the best agents for patients.
Immunocore’s first-in-human study of its bispecific, IMC-I109V, demonstrated early antiviral activity and a favorable safety profile, supporting continued development of the TCR bispecific candidate as a potential functional cure for chronic hepatitis B.
In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.
Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN.1 subvariants.
RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.
This week, read about the FDA's approval of IV antibiotic, Contepo, for complicated urinary tract infections, penicillin‑binding proteins, post-exposure doxycycline for Lyme disease prevention in young children, and more.
PBPs are more than static β lactam targets. Host conditions rewire PBP activity and peptidoglycan architecture, shaping tolerance, resistance, and how we design salvage regimens.
Despite a 2018 American Academy of Pediatrics clinical update that recommends use of postexposure prophylaxis for prevention of the tick-borne disease in children younger than 8 years, Wesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA, points out many clinicians are unaware of this. He also discusses its efficacy at preventing the disease in this patient population.
Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026.
IND clearance enables a randomized, double-blind study of IMM-529 with standard care, while a forthcoming USU Travelan field readout will guide dosing strategy.
In a multinational NEJM trial, a single 105-mg dose cut RSV hospitalizations by 84.2% and medically attended lower respiratory infection by 60.4% through 150 days, with safety similar to placebo.
The Centers for Disease Control and Prevention provided more information on a multistate outbreak and genomic testing.
The federal agency gave the nod to Meitheal Pharmaceuticals for its antibiotic, Contepo, an intravenous fosfomycin offering a new mechanism of action and a new option for adults with complicated urinary tract infections, including those caused by resistant gram-negative pathogens.
Results from a new survey taken this past summer show immunization confidence waning among the public and some factual uncertainty around immunization. In this time of disinformation and misinformation, Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about the vaccine as well as other strategies to increase immunization adherence.
At IDWeek, Anne Kasmar, MD, MSc, highlighted how expanding beyond traditional antibiotics, strengthening regulatory partnerships, and leveraging immunology are accelerating the next generation of antimicrobial resistance (AMR) solutions.
The foundation has unveiled its 2025 campaign, highlighting the deadly toll and long-term consequences of these infections through nationwide events, education initiatives, and tributes throughout November.
Prescribing of antiviral medication for children at risk of severe influenza decreased in COVID-19 pandemic despite unchanged treatment guidelines.
This week review more highlights from IDWeek, and why one researcher is predicting a milder avian influenza season.
Richard Webby, PhD, says increased wild bird immunity is a major factor for this year’s prediction.
Muhammad Sohaib Asghar, MBBS, MD, discusses why CDI deaths are concentrated in White patients and inpatient/long-term care settings, why mortality peaked in 2006–2015, and how stewardship and recurrence prevention are driving the recent decline.
In his new position, Gareth Morgan, MS, MBA, provides insights on antibiotic development strategies he would like to see during his tenure.
Bird migration has started. Surveillance and early detection are key, especially as it relates to H5N1 and predicting this year's respiratory virus season.
Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study.
The XpertHCV test from Cepheid enables rapid, point-of-care detection of hepatitis C infection in under an hour—helping to expand access to care and reduces follow-up loss.
At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.
Ashlan Kunz Coyne, PharmD, MPH, discusses the potential of combining antibiotics with phage mixture therapy in treating these types of infections.
George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.
